A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.
- 09 Nov 2017 Planned initiation date changed from 31 Jul 2017 to 1 Dec 2017.
- 19 Jun 2017 New trial record